Drug
Salanersen
Salanersen: highest development phase Phase 3, developed by Biogen. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Salanersen NCT07221669 | Phase 3 | Muscular Atrophy, Spinal |
| Salanersen NCT07444450 | Phase 3 | Muscular Atrophy, Spinal |
| Salanersen NCT07444476 | Phase 3 | Spinal Muscular Atrophy |
Latest
No recent events.
Follow Salanersen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.